Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cinclus Pharma Holding AB ( (SE:CINPHA) ) just unveiled an announcement.
Cinclus Pharma will publish its first-quarter report for January to March 2026 on May 13 at 08:00 CET and follow it with a live presentation at 10:00 CET, led by the CEO, CFO and R&D Director, including a Q&A session. Investors and other stakeholders can participate via webcast or teleconference, with materials and a recording made available on the company’s website, underscoring Cinclus Pharma’s efforts to maintain transparency as it advances its late-stage GERD pipeline.
The most recent analyst rating on (SE:CINPHA) stock is a Buy with a SEK60.00 price target. To see the full list of analyst forecasts on Cinclus Pharma Holding AB stock, see the SE:CINPHA Stock Forecast page.
More about Cinclus Pharma Holding AB
Cinclus Pharma Holding AB is a late-stage clinical pharmaceutical company focused on developing drugs for acid-related diseases and upper gastrointestinal disorders. Its lead candidate, linaprazan glurate, a prodrug of the P-CAB linaprazan originally developed by AstraZeneca, targets more effective healing and symptom relief in gastroesophageal reflux disease than current proton pump inhibitor therapies.
Average Trading Volume: 103,596
Technical Sentiment Signal: Sell
Current Market Cap: SEK563.1M
See more data about CINPHA stock on TipRanks’ Stock Analysis page.